Abstract:Hydrogels are three-dimensional solid-like structures with a wide range of applications in drug transport, tissue engineering, wound dressing, etc. We developed herein a new hydrogel by mixing 5′-guanosine monophosphate (5′-GMP) disodium salt (16 mM) and 1,4,5,8-naphthalene tetracarboxylic acid tetra potassium salt (NAP) (4 mM) in 4:1 (GMP:NAP) stoichiometry in aqueous media (pH ∼4 at 25 °C). The mechanical properties of the resulting hydrogel were investigated by rheological studies, which showed that the hydrogel formed at pH 4 is the most stable [storage modulus (Gꞌ) of ∼4000 Pa] and has higher endurance for the oscillatory strain (20% strain). Spectroscopic investigations provided insights into the unique self-assembly of 5′-GMP and NAP. Further, the composite exhibited pH-responsive hydrogelation over the pH range of 3–6, and the gel was transformed into a sol form at pH > 5. This stimuli-sensitive nature of the hydrogel was then exploited for the encapsulation and efficacious delivery of an anticancer drug, doxorubicin (DOX), specifically toward the colorectal cancer. Microscopic studies revealed the presence of a regular entangled fibrillar network for the hydrogels, which allowed for its exceptionally high drug loading capacity. The controlled release of DOX from the hydrogel was then studied at the physiological pH of the gastrointestinal tract, i.e. pH ∼7.4. The DOX-loaded hydrogel (DOX-Gel) exhibited a ∼82% release of DOX over 100 h at pH ∼7.4. The enhanced cellular toxicity of DOX was observed in CT-26 murine colorectal carcinoma cell lines treated with the DOX-loaded hydrogel compared to DOX only as manifested from the fluorescence-activated cell sortinganalyses and fluorescence microscopic studies. The fluorescence-activated cell sorting analysis showed a ∼4.5-fold increase in the drug internalization for the DOX-Gel as compared to DOX only formulations. The co-localization of DOX into the cell nucleus was confirmed from confocal microscopy. The in vivo drug delivery efficacy of this pH-responsive hydrogel was further assessed on an animal tumor model, Balb/c mice ( n = 9). A significant regression of ∼87.5% in the tumor volume was observed after 21 days of DOX-gel administration, in contrast to DOX only formulation, which showed only a ∼46.0% regression in the tumor volume. The blood reports of the non-treated control mice and the mice treated with DOX only indicated a metastatic behavior in comparison with the mice treated with the DOX-Gel. This, the present system, is a self-healable, injectable hydrogel, which makes it an ideal drug delivery vehicle with stimuli-responsive controlled drug release capabilities even in vivo .

Peptide‐based hydrogels as delivery systems for doxorubicin

Peptide-Based Hydrogels and Nanogels for Delivery of Doxorubicin

Doxorubicin-reinforced Supramolecular Hydrogels of RGD-derived Peptide Conjugates for Ph-Responsive Drug Delivery

Controlling Doxorubicin Release from a Peptide Hydrogel through Fine-Tuning of Drug–Peptide Fiber Interactions

RGD Peptide-Based Target Drug Delivery of Doxorubicin Nanomedicine.

Injectable small molecule hydrogel as a potential nanocarrier for localized and sustained in vivo delivery of doxorubicin

Hyaluronic Acid–Polyethyleneimine Nanogels for Controlled Drug Delivery in Cancer Treatment

Nanospheres of doxorubicin as cross-linkers for a supramolecular hydrogelation

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

Short and simple peptide-based pH-sensitive hydrogel for antitumor drug delivery

Injectable supramolecular hydrogels fabricated from PEGylated doxorubicin prodrug and α-cyclodextrin for pH-triggered drug delivery

Injectable Supramolecular Hydrogels Fabricated From Pegylated Doxorubicin Prodrug And Alpha-Cyclodextrin For Ph-Triggered Drug Delivery

Hydrogel-based platforms for site-specific doxorubicin release in cancer therapy

Injectable hyaluronic acid–cyclodextrin-based hydrogels for localized and sustained release of anticancer drugs

Biocompatible supramolecular hydrogels based on polysaccharide-modified hyaluronic acid for targeted delivering of doxorubicin

Targeted Chemotherapy for Breast Cancer Using an Intelligent Doxorubicin-Loaded Hexapeptide Hydrogel.

Injectable poly(ethylene glycol) hydrogels for sustained doxorubicin release

Injectable pH-responsive polypeptide hydrogels for local delivery of doxorubicin

Injectable doxorubicin-loaded hydrogels based on dendron-like beta-cyclodextrin-poly(ethylene glycol) conjugates

A self-healable and injectable hydrogel for pH-responsive doxorubicin drug delivery in vitro and in vivo for colon cancer treatment

Hydrophilicity/Hydrophobicity Reversable and Redox-Sensitive Nanogels for Anticancer Drug Delivery.